The global
structural heart devices market is set to witness a CAGR of
~9% in the next 5 years. The rising geriatric population &
corresponding rise in the prevalence of heart disease, technological
advancements in structural heart devices, regulatory approval for expanded
indications for several transcatheter heart valves, and increasing awareness
and favorable reimbursements for these procedures in key markets are some of
the pivotal factors driving the growth of the structural heart devices market.
However, high device costs, complex procedures, and stringent regulatory
hurdles continue to restrain market uptake.
Structural heart disease occurs when something is wrong with
one’s heart valves, walls, chambers or muscles. It exists from birth or
develops as one age. It includes conditions such as congenital heart disease,
cardiomyopathy, and heart valve disease. Heart valve devices, occluders &
delivery systems, annuloplasty rings, heart access systems, closure devices,
introducers, sheaths, balloon catheters, and accessories are some of the
devices used for structural heart disease treatment.
🔗 Want deeper insights?
Download the sample report:
https://meditechinsights.com/structural-heart-devices-market/request-sample/
Surge in valvular heart diseases expands the horizon for
structural heart devices
One of the most significant drivers propelling market growth
is the escalating prevalence of valvular heart disease, largely tied to the
aging global population. Chronic heart conditions such as mitral regurgitation,
aortic stenosis and heart failure, among others, are common due to aging
populations, sedentary lifestyle, and the growing impact of conditions like
hypertension and diabetes. Procedures like TAVR were earlier used to treat
high-risk surgical patients, but with significant technological advancements,
better patient outcomes and expanded clinical guidelines by healthcare
organizations, it is now being adopted for treating intermediate and low-risk
patients. As a result, there is a substantial rise in the number of patients,
which has led to the higher demand for structural heart devices like
transcatheter valves and occluders that offer less invasive alternatives
compared to traditional open-heart surgery. Further with advancements in
diagnostic tools, like echocardiography and CT scanning, ensure the early
diagnosis of structural heart diseases and their prevention, allowing more
patients to be channelled towards interventional therapies. Further, all the
developments have substantially increased procedure volumes and structural
heart device demand across healthcare systems.
Emerging solutions in mitral and tricuspid regurgitation
fuel structural heart market growth
In the field of structural heart disease, interventional
treatment for mitral regurgitation is one of the most challenging areas but
showcases huge market potential. Mitral valve regurgitation is the most common
type of heart valve disease in which the valve between the left heart chambers
does not close completely, allowing blood to leak backwards across the valve.
Similarly, tricuspid regurgitation is a highly prevalent but rarely treated
disease. It occurs when the valve’s flaps do not close properly. As a result,
blood can leak backwards into the atrium from the leaky tricuspid valve,
causing the heart to pump harder to move blood through the valve.
With the rise in several product innovations, including
transcatheter aortic valve replacement (TAVR), the MitraClip mitral valve
repair system and other products used in interventional procedures, there has
been a significant increase in the volume of structural heart procedures to
treat complex patients. Citing the lucrative prospects and unmet needs of the
market, players operating in the market are launching innovative devices to
address the demand. For instance,
- In
May 2025, Edwards Lifesciences received FDA approval for its SAPIEN 3 TAVR
platform, including SAPIEN 3 Ultra and Ultra RESILIA, to treat patients
with severe aortic stenosis who are asymptomatic
- In
April 2024, Abbott announced that the FDA had approved its TriClip
transcatheter edge-to-edge repair (TEER) system, which is the first
minimally invasive device designed to clip together the leaflets of a
leaky tricuspid valve, offering a safer alternative for patients with high
surgical risk
- In
January 2022, InnovHeart s.r.l., a developer of novel Transcatheter
Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve
disease raised $55 million in Series C financing to further develop the
Trans-septal Saturn Transcatheter Mitral Valve Replacement System
Organic and inorganic growth strategies adopted by
players to establish their foothold in the structural heart devices market
The structural heart devices market is marked by the
presence of both established and new players. Players operating in the market
adopt both organic and inorganic growth strategies, such as acquisitions and
new product launches, to garner market share. For instance,
- In
July 2024, Edwards Lifesciences announced that it had entered into an
agreement to acquire JenaValve Technology, a pioneer in transcatheter
treatment for aortic regurgitation, to expand its structural heart
portfolio
- In
February 2022, Genesis MedTech Group completed the acquisition
of JC Medical (JCM), a structural heart company engaged in the design and
development of transcatheter valve replacement products for the minimally
invasive treatment of structural heart diseases
Competitive Landscape Analysis
The global structural heart devices market is marked by the
presence of established and emerging market players such as Edwards
Lifesciences, Medtronic, Boston Scientific, Abbott, SMT, TTK Healthcare,
Micro Interventional Devices (MID), Lepu Medical, Microport, Teleflex,
Cordis, and CORCYM among others. Some of the key strategies
adopted by market players include new product development, strategic
partnerships and collaborations, and geographic expansion.
Gain a competitive edge-request a sample report now!
https://meditechinsights.com/structural-heart-devices-market/request-sample/
Global Structural Heart Devices Market
Segmentation
This report by Medi-Tech Insights provides the size of
the global structural heart devices market at the regional- and
country-level from 2023 to 2030. The report further segments the market based
on product and end-user.
Market Size & Forecast (2023-2030), By Product, USD
Million
- Heart
Valve Devices
- Surgical
Valves
- Transcatheter
Valves
- Transcatheter
Aortic Valve Replacement (TAVR)
- Transcatheter
Mitral Valve Replacement (TMVR)
- Delivery
Systems
- Occluders
- Annuloplasty
Rings
- Accessories
Market Size & Forecast (2023-2030), By End-user, USD
Million
- Hospitals
- Specialty
Clinics
- Others
Market Size & Forecast (2023-2030), By Region, USD
Million
- North
America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest
of Europe
- Asia
Pacific
- China
- India
- Japan
- Rest
of Asia Pacific
- Latin
America
- Middle
East & Africa
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research
& insights firm. Our clients include Fortune 500 companies, blue-chip
investors & hyper-growth start-ups. We have completed 100+ projects in
Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma
Services in the areas of market assessments, due diligence, competitive
intelligence, market sizing and forecasting, pricing analysis &
go-to-market strategy. Our methodology includes rigorous secondary research combined
with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply
side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
Comments
Post a Comment